ClinicalTrials.gg
CompletedNCT00200785Updated Jan 11, 2010Results posted

Identifying the Anti-Blood-Clotting Compounds in Garlic

An interventional study of garlic powder added to ambient water and garlic powder added to boiling water in Arteriosclerosis and Intracranial Arteriosclerosis, sponsored by National Center for Complementary and Integrative Health (NCCIH). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-01-11.

Sponsored by National Center for Complementary and Integrative Health (NCCIH) · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will seek to identify the compound(s) in garlic that is (are) responsible for its ability to prevent the formation of blood clots (prevent platelet aggregation) and to determine the maximally effective dose and duration of the benefits. This study will also determine whether "cooked" garlic (garlic powder added to boiling water, no allicin present) is as effective as "fresh" garlic (garlic powder added to ambient water, high allicin present) and, if more than one compound is involved, and whether their combined effects are more significant than the effects of each compound alone.

Read the detailed description

Published studies indicate that various types of undefined garlic products display antiplatelet activity. However, the compounds responsible for this antiplatelet effect have not been identified.

Acute studies. In acute (one day) studies, healthy participants will consume several doses of "fresh garlic" (garlic powder added to ambient water; up to the equivalent of 12 grams fresh garlic or 52 mg allicin) as a paste in a tuna sandwich. At 0, 2, 4, and 6 hours after consumption, the ability of platelets to aggregate in platelet-rich plasma (PRP) or in whole blood (WB), in response to a drug (collagen, ADP) that stimulates platelet aggregation, will be measured. After establishing the optimum dose and optimum time of the antiplatelet effect for each person, and if the effects are sufficiently strong, the effects of cooked garlic (garlic powder added to boiling water, no allicin present) and seven extracted fractions (oil, protein, fructans, etc.) will be determined, using the fractions at the same dose as their abundance in the established optimum dose of crushed fresh garlic.

Chronic studies. If only weak platelet effects are found for a high acute dose of "fresh" garlic, chronic studies will be conducted. In chronic studies, participants will consume 8.0 grams of "fresh garlic" (2.7 grams garlic powder added to ambient water, allicin content = 35 mg) as a paste in a tuna sandwich every day for four weeks and 8.0 grams of "boiled garlic" (2.7 grams garlic powder added to boiling water) in a sandwich every day for an additional four weeks, after a 1-week washout. The ability of platelets to aggregate in PRP and whole blood will be determined before and every week after garlic consumption begins and after the 1-week washout.

02

Conditions studied

  • Arteriosclerosis
  • Intracranial Arteriosclerosis

Keywords

  • garlic
03

In context

Arteriosclerosis

319 studies on the registry are indexed under Arteriosclerosis; 33 are open to participants now.

This study's enrollment of 9 is below the median of 143 across 184 interventional studies indexed under Arteriosclerosis.

Browse Arteriosclerosis studies →

Lead sponsor

National Center for Complementary and Integrative Health (NCCIH) is the lead sponsor of 223 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body mass index of 19 to 30 kg/m2
  • Plans to remain in the study area for the next year
  • Willingness to abstain from nonsteroidal anti-inflammatory drugs (NSAID drugs for 1 week prior to each study test
  • Willingness to abstain from consuming garlic and significant amounts of onion, chocolate, or purple grape juice for 3 days prior to each study test
  • Willingness to participate in all study tests

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Serious medical condition
  • Allergy to garlic or wheat
  • Tobacco use
  • Excessive alcohol consumption
  • Under psychiatric care
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    Garlic powder in ambient water

    high allicin

    Dietary Supplement: garlic powder added to ambient water

  • Experimental
    garlic powder in boiling water

    no allicin

    Dietary Supplement: garlic powder added to boiling water

Interventions

  • Dietary supplementgarlic powder added to ambient water

    consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks

    Also known as: Global Marketing Assoc., Inc.

  • Dietary supplementgarlic powder added to boiling water

    consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks

    Also known as: Global Marketing Assoc., Inc.

06

What researchers measure

Primary outcomes

  1. Percent Platelet Aggregation

    percent platelet aggregation in collagen-induced platelet aggregation in platelet rich plasma (PRP)

    Time frame: 4 weeks

Secondary outcomes

  1. Electrical Impedance in Ohms

    Electrical impedance (ohms) was measured using 0.5 mL of whole blood plus 0.5 mL saline in a Chronolog Whole Blood aggregometer. Ten mL of whole blood were collected and tested every week. There is no mathematical correlation between impedance (ohms) and percent aggregation.

    Time frame: 4 weeks

07

Results

Posted Jan 11, 2010

Participant flow

healthy participants were recruited in Utah county, Utah, in early 2006

First Intervention
Participant flow — First Intervention
MilestoneGarlic Powder: High AllicinGarlic Powder: No Allicin
Started96
Completed96
Not completed00
Washout Period of 1 Week
Participant flow — Washout Period of 1 Week
MilestoneGarlic Powder: High AllicinGarlic Powder: No Allicin
Started96
Completed96
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneGarlic Powder: High AllicinGarlic Powder: No Allicin
Started96
Completed96
Not completed00

Outcome measures

PrimaryPercent Platelet Aggregation

percent platelet aggregation in collagen-induced platelet aggregation in platelet rich plasma (PRP)

Time frame:
4 weeks
Reported as:
Mean · percent platelet aggregation
Percent Platelet Aggregation
percent platelet aggregationGarlic Powder: High AllicinGarlic Powder: No Allicin
Percent Platelet Aggregation71.4 ± 4.372.5 ± 5.5
SecondaryElectrical Impedance in Ohms

Electrical impedance (ohms) was measured using 0.5 mL of whole blood plus 0.5 mL saline in a Chronolog Whole Blood aggregometer. Ten mL of whole blood were collected and tested every week. There is no mathematical correlation between impedance (ohms) and percent aggregation.

Time frame:
4 weeks
Reported as:
Mean · ohms
Electrical Impedance in Ohms
ohmsGarlic Powder: High AllicinGarlic Powder: No Allicin
Electrical Impedance in Ohms13.8 ± 1.515.0 ± 1.5

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Garlic Powder: High Allicin—0/9 (0%)0/9 (0%)
Garlic Powder: No Allicin—0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
<=18 years000.0
Between 18 and 65 years9615.0
>=65 years000.0
Age Continuous
Age Continuous(years)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
Mean32.2 ± 13.736.5 ± 15.132.2 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
Female437.0
Male538.0
Region of Enrollment
Region of Enrollment(participants)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
United States9615.0
electrical impedance (ohms) at 0 weeks
electrical impedance (ohms) at 0 weeks(ohms)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
Mean12.7 ± 1.215.0 ± 1.613.9 ± 1.4
percent platelet aggregation at 0 weeks
percent platelet aggregation at 0 weeks(percent platelet aggregation)Garlic Powder: High AllicinGarlic Powder: No AllicinTotal
Mean76.0 ± 1.671.8 ± 5.773.9 ± 3.7
08

Study locations

1 site
  • Silliker, Inc./Plant Bioactives Research Institute
    Orem, Utah 84058, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
Mar 2006
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results first posted
Jan 11, 2010
Last update
Jan 11, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00200785
First posted
Sep 20, 2005
Start date
Mar 2006
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Jan 11, 2010
Last update
Jan 11, 2010

Study contacts

Larry D. Lawson, PhD
principal investigator · Silliker, Inc./Plant Bioactives Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion